Just out: Double blind placebo controlled randomized trial of oral triplet Ixazomib-Rd vs Rd as frontline therapy of multiple myeloma. Helps elderly patients unable to travel.
Personally gratifying as 11th randomized trial as a lead investigator. ashpublications.org/blood/article-…
Personally gratifying as 11th randomized trial as a lead investigator. ashpublications.org/blood/article-…
Ixazomib is an oral proteasome inhibitor that is given once a week.
One pill once a week is a convenient way of delivering proteasome inhibitor therapy that otherwise takes a trip to the clinic.
One pill once a week is a convenient way of delivering proteasome inhibitor therapy that otherwise takes a trip to the clinic.
CR and VGOR rates were higher with ixazomib-Rd vs placebo-Rd.
Median PFS: 35.3 months with ixazomib Rd vs 21.8 months with placebo-Rd, P = 0.073.
Median PFS: 35.3 months with ixazomib Rd vs 21.8 months with placebo-Rd, P = 0.073.
I think efficacy of ixazomib is less than bortezomib or carfilzomib. But in patients for whom travel once a week to clinic is difficult due to advanced age or frailty, ixazomib is a good alternative.
Especially during COVID times, and in high risk patients.
Especially during COVID times, and in high risk patients.
Ixazomib has previously shown significant clinical efficacy in relapsed myeloma and in maintenance therapy in double blind placebo controlled RCTs.
So the P value of 0.07 for PFS is not a concern for me. The drug works. We underestimated the sample size while designing the trial
So the P value of 0.07 for PFS is not a concern for me. The drug works. We underestimated the sample size while designing the trial
• • •
Missing some Tweet in this thread? You can try to
force a refresh
